VC Deals Analysis: From Famine To Feast, 2017 Bloats With May Haul
Executive Summary
The venture financing climate has been somewhat dull so far this year but the investment activity levels enjoyed a much-needed boost in May. The month's haul of transactions not only brought in the quantity – with the highest deal volume to date – but also quality, high-value rounds.
You may also be interested in...
VC Deals Analysis: Quarter-Billion Round Hikes September Takings To Five-Year High
September benefitted from two nine-figure venture financing rounds, including a $250m round by consumer genetic test service provider 23andme. These bumper deals significantly boost the total takings in 2017 so far to the extent that the year looks likely to beat 2016.
Market Intel: Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth
End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.
VC Deals Analysis: Strong In Volume, Soft In Value
June marked a month with the highest deal volume this year to date, although the value of most deals wallowed in the low range. Nonetheless the previous bumper months of March and May meant that the first half of 2017 can boast of having raised the most money, compared to the last four years.